Status:
UNKNOWN
Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Respiratory Distress Syndrome, Adult
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Pandemic SARS-CoV-2 (COVID-19) respiratory infection is responsible for more than 4,000 deaths, mainly (67%) secondary to acute respiratory distress syndromes (ARDS). ARDS is usually associated with a...
Detailed Description
Clinical metagenomics is a technique that has the ability to explore the host's inflammatory response by transcriptomics and the co-infection(s) of all microorganisms. For this, an accredited method a...
Eligibility Criteria
Inclusion
- Patient admitted to intensive care for ARDS (Berlin definition) documented at SARS-CoV-2
- Major patient (age ≥ 18 years)
- Collection of the non-opposition of the patient or his support person, family member or close friend (newsletter)
Exclusion
- Minor patient
- Refusal to participate in the study
- Patient protected by law
- Prisoner
Key Trial Info
Start Date :
March 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04516486
Start Date
March 9 2020
End Date
December 31 2020
Last Update
August 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Henri Mondor
Créteil, France, 94000